India’s second-largest IT company Infosys slashed its revenue guidance for the fiscal 2025 to 1-3 percent, below analyst estimates, as weakness continued in discretionary and digital projects.
What Is Type 1 Diabetes? Type 1 diabetes is a condition ... it can figure out your average blood sugar levels over the past 3 months with one small blood sample. It does that by counting the ...
Shares of Bharti Airtel are currently trading at Rs 1262.1, marking a 3.76% increase for the day. Over the past week, the stock has seen a slight decline of -1.05% in returns. Bharti Airtel is ...
Shares of Rivian, up as much as 3.4% on Wednesday, pared almost all of its gains after the news. The shares closed up 1% on Thursday. "This was a difficult decision, but a necessary one to support ...
A short seller called Capybara Research recently published a report forecasting that SoundHound AI stock was worth only $1 -- implying that ... incurring hefty losses. 3. Don't take everything ...
Norway’s $1.6 trillion sovereign wealth fund fell short ... Norges Bank Investment Management, which manages Norway’s fossil wealth, returned 6.3%, or $110 billion, it said in a statement ...
The trial showed that gepotidacin (oral, two doses of 3,000mg) was non-inferior with 92.6% success rates when compared to 91.2% success rates for intramuscular (IM) ceftriaxone (500mg) plus oral ...
A short seller called Capybara Research recently published a report forecasting that SoundHound AI stock was worth only $1 -- implying that the shares could crater by 75% from current trading levels.
The goal preserved Leverkusen's incredible unbeaten record since a 3-0 reverse at Bochum on 27 May last year, 328 days ago, and booked a last-four meeting with Brighton's conquerors Roma ...
The trial showed that gepotidacin (oral, two doses of 3,000mg) was non-inferior, with 92.6% success rates, compared to 91.2% success rates for intramuscular ceftriaxone (500mg) plus oral azithromycin ...
two doses of 3,000mg) was non-inferior, with 92.6% success rates, compared to 91.2% success rates for intramuscular ceftriaxone (500mg) plus oral azithromycin (1,000mg) combined therapy ...
two doses of 3,000mg) was non-inferior with 92.6% success rates when compared to 91.2% success rates for intramuscular (IM) ceftriaxone (500mg) plus oral azithromycin (1,000mg) combined therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results